MedTrace Logo

Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome

NCT01145612 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2010-08-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of Losartan versus Atenolol in the progression of aortic dilatation in patients with Marfan syndrome.

Conditions

  • Marfan Syndrome

Interventions

DRUG

Losartan

Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg

DRUG

Atenolol

Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg

Sponsors & Collaborators

  • Ministry of Health, Spain

    collaborator OTHER_GOV

  • Forteza, Albert, M.D.

    lead INDIV

Principal Investigators

  • Alberto Forteza, Dr

  • Arturo Evangelista, Dr

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01145612 on ClinicalTrials.gov